Familial hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism and increases the risk of premature cardiovascular diseases. In patients with FH, platelet function may be activated; however, the extent of this activation and its etiology are unclear. We aimed to evaluate the mean platelet volume (MPV), a marker of platelet activation, in patients with FH. The study group consisted of 164 patients with FH and 160 control patients. Controls were matched for age, gender, hypertension, and smoking. The MPV was significantly higher in patients with FH than in controls (9.2 ± 0.4 vs 7.9 ± 0.6 fL, respectively; P < .001). Platelet count was significantly lower among patients with FH when compared to control patients (259 ± 51 vs 272 ± 56 × 103/L, respectively; P = .03). In linear regression analysis, MPV was independently associated only with total cholesterol (β = .6, 95% confidence interval: 0.004-0.008, P < .001). We have shown that MPV was increased in patients with FH and that it was independently associated with total cholesterol level.
HovinghGKDavidsonMHKasteleinJJO’ConnorAM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34(13):962–971.
2.
HopkinsPNTothPPBallantyneCMRaderDJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S9–S17.
3.
NeilHAHuxleyRRHawkinsMMDurringtonPNBetteridgeDJHumphriesSE. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2003;170(1):73–78.
4.
ChengHMYeZXChiouKRLinSJCharngMJ. Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. Eur J Clin Invest. 2007;37(3):197–206.
5.
KasteleinJJWiegmanAde GrootE. Surrogate markers of atherosclerosis: impact of statins. Atheroscler Suppl. 2003;4(1):31–36.
6.
DiMinnoGSilverMJCerboneAMRainoneAPostiglioneAManciniM. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis. 1986;6(2):203–211.
7.
CarvalhoACColmanRWLeesRS. Platelet function in hyperlipoproteinemia. N Engl J Med. 1974;290(8):434–438.
8.
CorashLAndersenJPoindexterBJSchaeferEJ. Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis. 1981;1(6):443–448.
9.
BlahaMPeckaMUrbankovaJ. Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia. Transfus Apher Sci. 2004;30(2):83–87.
10.
AviramMHusseinORosenblatMSchlezingerSHayekTKeidarS. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998;31(1):39–45.
11.
VizioliLMuscariSMuscariA. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509–1515.
12.
KamathSBlannADLipGY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22(17):1561–1571.
13.
ParkYSchoeneNHarrisW. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5-6):301–306.
14.
ChuSGBeckerRCBergerPB. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148–156.
15.
SinzingerHPirichCBednarJO’GradyJ. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. Thromb Res. 1996;82(4):291–301.
16.
TremoliEMadernaPColliSMorazzoniGSirtoriMSirtoriCR. Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinaemic patients. Eur J Clin Invest. 1984;14(5):329–333.
17.
World Health Organization. Familial Hypercholesterolemia—Report of a Second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999. WHO publication no. WHO/HGN/FH/CONS/99.2.
18.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
19.
StokesKYCooperDTailorAGrangerDN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med. 2002;33(8):1026–1036.
20.
CroftKDBeilinLJVandongenRRouseIMasareiJ. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemia. Atherosclerosis. 1990;83(2-3):101–109.
21.
MazeaudMMDrissFLe Quan SangKH. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. Atherosclerosis. 1992;94(2-3):201–211.
22.
BoosCJLipGY. Assessment of mean platelet volume in coronary artery disease—what does it mean?Thromb Res. 2007;120(1):11–13.
23.
GilesHSmithREMartinJF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24(1):69–72.
24.
PathansaliRSmithNBathP. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets. 2001;12(5):292–297.
25.
CelebiOOCanbayACelebiSSahinDAydogduSDikerE. The effect of admission mean platelet volume on TIMI frame count measured after fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars. 2009;37(5):307–311.
26.
ThakurMLWelchMJJoistJHColemanRE. Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res. 1976;9(4):345–357.
27.
SmithCCBetteridgeDJ. Reduced platelet serotonin content and release in familial hypercholesterolaemia. Atherosclerosis. 1997;130(1-2):87–92.
28.
MartinJFKristensenSDMathurAGroveELChoudryFA. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol. 2012;9(11):658–670.
29.
UelandTVissersMNWiegmanA. Increased inflammatory markers in children with familial hypercholesterolaemia. Eur J Clin Invest. 2006;36(3):147–152.
30.
GasparyanAYAyvazyanLMikhailidisDPKitasGD. Mean platelet volume: a link between thrombosis and inflammation?Curr Pharm Des. 2011;17(1):47–58.
31.
YarliogluesMKayaMGArdicI. Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press. 2011;20(2):92–97.
32.
BlannADNadarSKLipGY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24(24):2166–2179.
33.
GuardamagnaOAbelloFSaraccoPBaraccoVRolfoEPirroM. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. 2009;207(2):471–475.
34.
PirichCGaszoAGraneggerSSinzingerH. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. Thromb Res. 1999;96(3):219–227.
35.
BlahaMKostalMLanskaM. The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination. Atheroscler Suppl. 2013;14(1):77–81.
36.
JagroopIAPersaudJWMikhailidisDP. A new rapid method to measure human platelet cholesterol: a pilot study. Clin Appl Thromb Hemost. 2011;17(6):578–584.
